» Articles » PMID: 27244558

CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium Tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease

Overview
Journal PLoS Pathog
Specialty Microbiology
Date 2016 Jun 1
PMID 27244558
Citations 181
Authors
Affiliations
Soon will be listed here.
Abstract

IFN-γ-producing CD4 T cells are required for protection against Mycobacterium tuberculosis (Mtb) infection, but the extent to which IFN-γ contributes to overall CD4 T cell-mediated protection remains unclear. Furthermore, it is not known if increasing IFN-γ production by CD4 T cells is desirable in Mtb infection. Here we show that IFN-γ accounts for only ~30% of CD4 T cell-dependent cumulative bacterial control in the lungs over the first six weeks of infection, but >80% of control in the spleen. Moreover, increasing the IFN-γ-producing capacity of CD4 T cells by ~2 fold exacerbates lung infection and leads to the early death of the host, despite enhancing control in the spleen. In addition, we show that the inhibitory receptor PD-1 facilitates host resistance to Mtb by preventing the detrimental over-production of IFN-γ by CD4 T cells. Specifically, PD-1 suppressed the parenchymal accumulation of and pathogenic IFN-γ production by the CXCR3+KLRG1-CX3CR1- subset of lung-homing CD4 T cells that otherwise mediates control of Mtb infection. Therefore, the primary role for T cell-derived IFN-γ in Mtb infection is at extra-pulmonary sites, and the host-protective subset of CD4 T cells requires negative regulation of IFN-γ production by PD-1 to prevent lethal immune-mediated pathology.

Citing Articles

CD4 T cell dysfunction is associated with bacterial recrudescence during chronic tuberculosis.

Chang E, Cavallo K, Behar S bioRxiv. 2025; .

PMID: 39896548 PMC: 11785196. DOI: 10.1101/2025.01.22.634376.


Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals.

Lyu J, Narum D, Baldwin S, Larsen S, Bai X, Griffith D Front Immunol. 2024; 15:1427559.

PMID: 39717773 PMC: 11663721. DOI: 10.3389/fimmu.2024.1427559.


Immune correlates of protection as a game changer in tuberculosis vaccine development.

Wang J, Fan X, Hu Z NPJ Vaccines. 2024; 9(1):208.

PMID: 39478007 PMC: 11526030. DOI: 10.1038/s41541-024-01004-w.


Cytokines in gingivitis and periodontitis: from pathogenesis to therapeutic targets.

Neurath N, Kesting M Front Immunol. 2024; 15:1435054.

PMID: 39253090 PMC: 11381234. DOI: 10.3389/fimmu.2024.1435054.


Immune checkpoint inhibitors in infectious disease.

King H, Lewin S Immunol Rev. 2024; 328(1):350-371.

PMID: 39248154 PMC: 11659942. DOI: 10.1111/imr.13388.


References
1.
Carneiro-Sampaio M, Coutinho A . Immunity to microbes: lessons from primary immunodeficiencies. Infect Immun. 2007; 75(4):1545-55. PMC: 1865715. DOI: 10.1128/IAI.00787-06. View

2.
Flynn J, GOLDSTEIN M, Chan J, Triebold K, Pfeffer K, Lowenstein C . Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995; 2(6):561-72. DOI: 10.1016/1074-7613(95)90001-2. View

3.
Bertholet S, Ireton G, Ordway D, Windish H, Pine S, Kahn M . A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med. 2010; 2(53):53ra74. PMC: 3110937. DOI: 10.1126/scitranslmed.3001094. View

4.
Nandi B, Behar S . Regulation of neutrophils by interferon-γ limits lung inflammation during tuberculosis infection. J Exp Med. 2011; 208(11):2251-62. PMC: 3201199. DOI: 10.1084/jem.20110919. View

5.
Sakai S, Mayer-Barber K, Barber D . Defining features of protective CD4 T cell responses to Mycobacterium tuberculosis. Curr Opin Immunol. 2014; 29:137-42. PMC: 4122329. DOI: 10.1016/j.coi.2014.06.003. View